Riociguat | List of Frontiers open access articles

Original Research

Published on 18 Sep 2024

Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin

in Drug Metabolism and Transport

Qingqing Li
Xiaohai Chen
Siping Zhang
Wanshu Li
Hangjuan Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1470377

2,234 views
2 citations

Case Report

Published on 01 Dec 2022

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

in Pediatric Cardiology

L. T. Domingo
D. D. Ivy
S. H. Abman
A. M. Grenolds
J. T. MacLean
J. A. Breaux
K. J. Minford
B. S. Frank

Frontiers in Pediatrics

doi 10.3389/fped.2022.1014922

6,380 views
16 citations

Original Research

Published on 26 Jan 2023

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

in Pharmacoepidemiology

Yu-Yang Liu
Yi-Yang Qu
Shang Wang
Ci-Jun Luo
Hong-Ling Qiu
Hui-Ting Li
Ping Yuan
Lan Wang
Jin-Ling Li
Rong Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1052546

6,551 views
2 citations

Original Research

Published on 29 Mar 2023

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

in Respiratory Pharmacology

Daniel Morales-Cano
Jose Luis Izquierdo-García
Bianca Barreira
Sergio Esquivel-Ruiz
Maria Callejo
Rachele Pandolfi
Palmira Villa-Valverde
Ignacio Rodríguez
Angel Cogolludo
Jesus Ruiz-Cabello

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1021535

5,689 views
5 citations

Original Research

Published on 01 Oct 2021

Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway

in Respiratory Pharmacology

Lijun Li
Minghui Yin
Liqing Hu
Xiaoting Tian
Xiangrong He
Congke Zhao
Ying Li
Qianbin Li
Xiaohui Li

Frontiers in Pharmacology

doi 10.3389/fphar.2021.691405

4,277 views
12 citations

Original Research

Published on 03 Nov 2021

Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics

in Translational Medicine

Xiang Xu
Hanlu Li
Qingxia Wei
Xin Li
Yanying Shen
Ge Guo
Yibing Chen
Kunlun He
Chunlei Liu

Frontiers in Medicine

doi 10.3389/fmed.2021.742436

7,442 views
13 citations

Clinical Trial

Published on 12 Jun 2024

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial

in Translational Pharmacology

Yu-zhou Gui
Wei Wang
Qing-qing Wu
Qi-chen Ding
Hong-jie Qian
Qiu-bei Lu
Ying-jun Zhang
Yu-lei Zhuang
Li Deng
Ying-lin Zuo

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1359939

3,932 views
5 citations

Correction

Published on 20 Feb 2023

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

in Pharmacoepidemiology

Yu-Yang Liu
Yi-Yang Qu
Shang Wang
Ci-Jun Luo
Hong-Ling Qiu
Hui-Ting Li
Ping Yuan
Lan Wang
Jin-Ling Li
Rong Jiang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1155631

1,954 views

Correction

Published on 12 Jun 2023

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

in Respiratory Pharmacology

Daniel Morales-Cano
Jose Luis Izquierdo-García
Bianca Barreira
Sergio Esquivel-Ruiz
Maria Callejo
Rachele Pandolfi
Palmira Villa-Valverde
Ignacio Rodríguez
Angel Cogolludo
Jesus Ruiz-Cabello

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1228923

1,890 views

Articles

Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Novel Pyrazolo[3,4-b] Pyridine Derivative (HLQ2g) Attenuates Hypoxic Pulmonary Hypertension via Restoring cGKI Expression and BMP Signaling Pathway

Novel Targets in a High-Altitude Pulmonary Hypertension Rat Model Based on RNA-seq and Proteomics

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a soluble guanylate cyclase stimulator, HEC95468, in healthy volunteers: a randomized, double-blinded, placebo-controlled phase 1 trial

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Corrigendum: Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model